Volume 4.44 | Nov 12

Pulmonary Cell News 4.44 November 12, 2015
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PULCN on Twitter
Pseudomonas aeruginosa Pyocyanin Modulates Mucin Glycosylation with Sialyl-Lewisx to Increase Binding to Airway Epithelial Cells
Researchers found pyocyanin to be a potent inducer of sialyl-Lewisx in both mouse airways and in primary and immortalized cystic fibrosis (CF) and non-CF human airway epithelial cells. [Mucosal Immunol] Abstract
Model the Human Respiratory Epithelium with PneumaCult™-ALI. Click to View Data.
PUBLICATIONS (Ranked by impact factor of the journal)
The Dual Phosphodiesterase 3 and 4 Inhibitor RPL554 Stimulates CFTR and Ciliary Beating in Primary Cultures of Bronchial Epithelia
Scientists demonstrated that phosphodiesterase inhibition by RPL554, a drug which has been shown to cause bronchodilation in asthma and COPD patients, stimulates CFTR-dependent ion secretion across bronchial epithelial cells isolated from patients carrying the R117H/F508del cystic fibrosis genotype. [Am J Physiol Lung Cell Mol Physiol] Abstract

Combinations of Differentiation Markers Distinguish Subpopulations of Alveolar Epithelial Cells in Adult Lung
The authors investigated if subpopulations of alveolar epithelial cells exist that represent various stages in transdifferentiation from alveolar type II to alveolar type I cell phenotypes in normal adult lung and if they can be identified using combinations of cell-specific markers. [Am J Physiol Lung Cell Mol Physiol] Abstract

Monomethylarsonous Acid (MMAIII) Has an Adverse Effect on the Innate Immune Response of Human Bronchial Epithelial Cells to Pseudomonas aeruginosa
This study examined the effects on P. aeruginosa induced cytokine secretion by human bronchial epithelial cells by inorganic sodium arsenite and two major metabolites, MMAIII and dimethylarsenic acid, at concentrations relevant to the U.S. population. [PLoS One] Full Article

Wnt5a Reverses the Inhibitory Effect of Hyperoxia on Transdifferentiation of Alveolar Epithelial Type II Cells to Type I Cells
Alveolar epithelial type II cells (AECIIs) transfected with Wnt5a gene and exogenous Wnt5a were used to examine whether Wnt5a contributes to the transdifferentiation of AECIIs to AECIs. Scientists showed that hyperoxia inhibited the transdifferentiation of AECIIs to AECIs in vitro, which is represented by biomarkers of two types of cell that remained unchanged. [J Physiol Biochem] Abstract


Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC
Researchers discovered that depleting NAD(P)H/quinone oxidoreductase 1 (NQO1) expression in A549 and H292 lung adenocarcinoma cells caused an increase in reactive oxygen species formation, inhibited anchorage-independent growth, increased anoikis sensitization and decreased 3D tumor-spheroid invasion. [Mol Cancer Res] Abstract

Critical Role of miR-155/FoxO1/ROS Axis in the Regulation of Non-Small Cell Lung Carcinomas
The authors evaluated the role of miR-155 in non-small cell lung carcinoma (NSCLC) cell proliferation and explored the possible molecular mechanisms. They found that miR-155 expression was increased in NSCLC tissues and cell lines. [Tumor Biol] Abstract

Fra-1 Is Upregulated in Lung Cancer Tissues and Inhibits the Apoptosis of Lung Cancer Cells by the P53 Signaling Pathway
Investigators showed that fos-related antigen-1 (Fra-1) was overexpressed in the lung cancer tissues when compared with the level in the adjacent non-cancerous tissues. To explore the possible mechanism of Fra-1 in lung cancer, they elucidated the effect of Fra-1 on the apoptosis of lung cancer H460 cells, and found that the rate of cell apoptosis was decreased in the H460/Fra-1 cells compared with the H460 or H460/vector cells. [Oncol Rep] Abstract

Effects of 2-Methoxyestradiol on Apoptosis and HIF-1α and HIF-2α Expression in Lung Cancer Cells under Normoxia and Hypoxia
Researchers compared the effects of 2-methoxyestradiol on cell growth, apoptosis, hypoxia-inducible factor 1α (HIF-1α) and HIF-2α gene and protein expression in A549 cells under normoxic and hypoxic conditions. [Oncol Rep] Abstract

Del-1 Overexpression Potentiates Lung Cancer Cell Proliferation and Invasion
Scientists investigated the effect of developmental endothelial locus-1 (Del-1) on the features of human lung carcinoma cells. Del-1 mRNA was found to be significantly decreased in the human lung adenocarcinoma cell lines A549, H1299 and EKVX, compared to in human normal lung epithelial BEAS-2B cells and MRC-5 fibroblasts. [Biochem Biophys Res Commun] Abstract

Learn More: Standardized Tools for Cancer Research
Targeted Therapies for Treatment of Non-Small Cell Lung Cancer – Recent Advances and Future Perspectives
The authors review the development of targeted therapies for the treatment of advanced or metastatic non-small cell lung cancer, including those already in clinical practice and those in early trials. [Int J Cancer] Abstract

PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer
The authors discuss the main PTEN/PI3K/AKT pathway alterations found in non-small-cell lung cancer, as well as the cell processes regulated by PTEN/PI3K/AKT leading to tumorigenesis. [Pharmacogenomics] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
OncoMed Presents Data from Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs
Data from three posters covered Phase Ia safety, biomarker and anti-tumor activity of brontictuzumab, novel biomarker discoveries related to vantictumab in non-small cell lung cancer and preclinical characterization of safety and efficacy for anti-DLL4/VEGF bispecific. [Press release from OncoMed Pharmaceuticals Inc. discussing research presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston] Press Release

DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)
DelMar Pharmaceuticals, Inc. presented data on the benefit of VAL-083 in combination with platinum-based chemotherapy regimens in the treatment of NSCLC. [Press release from DelMar Pharmaceuticals, Inc. discussing research presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston] Press Release

Positive CAVATAKTM Clinical Data Presented
Viralytics Limited announced positive data from two clinical studies of its lead drug candidate CAVATAKTM. [Press release from Viralytics Limited discussing research presented at the 30th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC), National Harbor] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine.
Request a free wallchart from Nature.
Genocea Announces Immuno-Oncology Research Collaboration with Memorial Sloan Kettering Cancer Center
Genocea Biosciences, Inc. announced a collaboration with Memorial Sloan Kettering Cancer Center to screen the T cell responses of melanoma and non-small cell lung cancer patients treated with checkpoint inhibitors against the complete repertoire of patient-specific putative cancer neoantigens. [Genocea Biosciences, Inc.] Press Release

Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK™ and KEYTRUDA® in Lung and Bladder Cancer
Viralytics Limited announced that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc. (MSD) to evaluate the combination of Viralytics’investigational cancer immunotherapy CAVATAK™, with MSD’s KEYTRUDA®, an antiPD-1 (programmed death receptor-1) therapy. [Viralytics Limited] Press Release

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
Merck KGaA and Pfizer announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab in a treatment naive advanced NSCLC setting. [Merck KGaA] Press Release

Concert Pharmaceuticals Initiates Phase I Multiple Ascending Dose Trial with CTP-656 for Cystic Fibrosis
Concert Pharmaceuticals, Inc. announced that it has initiated a Phase I multiple ascending dose clinical trial with CTP-656. CTP-656 is a novel, potentially disease-modifying treatment for cystic fibrosis for use as monotherapy as well as in combination with other CFTR modulators. [Concert Pharmaceuticals, Inc.] Press Release

$1.225M Viertel Fellowship to Advance Critical Lung Research
Lung researcher Dr Marie-Liesse Asselin-Labat has won a competitive $1.225 million Viertel Fellowship for an ambitious research program to advance our understanding of lung development and cancer. [The Walter and Eliza Hall Institute of Medical Research] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW German Cancer Congress 2016
February 24-27, 2016
Berlin, Germany

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Postdoctoral Fellow – Cancer Biology (Cold Spring Harbor Laboratory)

NEW Professorship – Respiratory Science (University of Cambridge)

Postdoctoral Positions – Fibrotic Remodeling of the Lung (University of Vermont)

Postdoctoral Positions – Cancer (University of Texas MD Anderson Cancer Center)

Post-Doctoral Fellow – Lung Microbiome Research and Asthma (University of Michigan)

PhD Studentships – Cancer Research (University of Cambridge)

Postdoctoral Position – Pulmonary Research (Helmholtz Association)

Postdoctoral Position – Lung Biology Research (University of Southern California)

Postdoctoral Fellowship – Developmental Cell Biology and Regenerative Medicine (University of California San Francisco)

Postdoctoral Researcher – Molecular Mechanisms of Pulmonary Diseases (Eastern Virginia Medical School)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us